Please ensure Javascript is enabled for purposes of website accessibility

Why Neurocrine Biosciences Stock Jumped Today

By Keith Speights - Updated Mar 25, 2021 at 3:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock is being added to a mid-cap index.

What happened

Shares of Neurocrine Biosciences (NBIX 0.90%) were jumping 12.5% higher as of 3:22 p.m. EDT on Thursday. The big gain came after it was announced that Neurocrine will replace O-I Glass in the S&P MidCap 400 Index

So what

The addition of the biotech stock to the S&P MidCap 400 Index means that any funds tracking this index must buy shares of Neurocrine. This prospect of significant buying is music to the ears of Neurocrine shareholders.

$1 bill folded into an arrow pointing up

Image source: Getty Images.

However, Neurocrine's addition to the mid-cap index should be viewed as a temporary boost. Whether or not the stock can hold onto its gains will depend on its financial performance and its clinical results.

The company hasn't fared well on the latter front recently. Earlier this month, Neurocrine announced disappointing results from a phase 2 study of luvadaxistat in treating adults with negative symptoms of schizophrenia. 

Now what

Neurocrine has more potential catalysts on the way. The company expects to report results from a late-stage study of valbenazine in treating chorea (abnormal involuntary movements) in Huntington's disease in the fourth quarter of 2021. Neurocrine also plans to begin another late-stage study of the drug in treating a neurological indication. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Neurocrine Biosciences, Inc. Stock Quote
Neurocrine Biosciences, Inc.
$84.88 (0.90%) $0.76
Owens-Illinois, Inc. Stock Quote
Owens-Illinois, Inc.
$13.85 (4.45%) $0.59

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.